ABSTRACT
We present a case of annular polycylic type of subacute lupus erythematosus which fulfilled the criteria of systemic lupus erythematosus and was associated with protein losing enteropathy. A 37-year-old male had erythematous annular rashes with several painful, scattered ulcers and a generalized edematous appearance. Abnormal laboratory findings were hypoalbuminemia, low complement, positive Anti-Ro, La, and ANA in a speckled pattern. Tc-99m human serum albumin scintigraphy revealed extravasation within the small bowel. The histopathologic findings showed vacuolar degeneration, upper dermal edema and cleft with perivascular lymphocytic infiltration. Direct IF revealed granular deposition of IgG along the dermo-epidermal junction. The patient was treated with intravenous steroids and oral hydroxychloroquine.
Subject(s)
Adult , Humans , Male , Complement System Proteins , Edema , Exanthema , Hydroxychloroquine , Hypoalbuminemia , Immunoglobulin G , Lupus Erythematosus, Cutaneous , Lupus Erythematosus, Systemic , Protein-Losing Enteropathies , Radionuclide Imaging , Serum Albumin , Steroids , UlcerABSTRACT
We present a case of a young male with a five year history of a hair-loss patch presenting linear distribution on the scalp. A biopsy specimen revealed a lymphocytic panniculitis and fat degeneration with mucin deposit. Focal hydropic degeneration of basal cells was also evident. Direct immuno-fluorescence revealed peribulbar granular deposits of IgM, IgA and C3. Antinuclear antibody was negative. Clinical appearance was unusual but histological examination revealed linear lupus erythematosus profundus. To our knowledge, only one other case of linear lupus erythematosus profundus on the scalp has been reported in English written literature until now.
Subject(s)
Humans , Male , Alopecia , Antibodies, Antinuclear , Biopsy , Immunoglobulin A , Immunoglobulin M , Mucins , Panniculitis , Panniculitis, Lupus Erythematosus , ScalpABSTRACT
PURPOSE: The current organ shortage in renal transplantation underscores the importance of optimizing long- term graft survival. Despite the significant improvement in the results of renal transplantation since the introduction of cyclosporine, graft loss after fist year of transplantation remains a significant and unresolved problem. This study showed renal function at 1 month after transplantation as a prognostic factor influencing long-term renal graft survival. METHODS: The results of 683 cases of renal transplantations performed from 1978 to 2001 in our center were analysed. We divided into 3 groups according to the serum creatinine level (group 1: 60), donor sex, donor type (related, unrelated, cadevaric), recipient age (60), recipient sex, HLA matching, acute rejection, delayed graft function were also analysed. RESULTS: The acute rejection rates in each group were 17.1%, 40.6%, 71.7% retrospectively (P=0.000). The frequencies of delayed graft function were 3.9%, 9.0%, 36.2% retrospectively (P=0.000). There was significant difference of graft survival between each group (P=0.000). In addition, graft survival in group with acute rejection showed significant difference according to creatinine level at 1 month. CONCLUSION: We can predict long-term graft survival and early renal function through serum creatinine levels after transplantation. Therefore, serum creatinine level at first month of transplantation was prognostic factor in predicting long-term graft survival.
Subject(s)
Humans , Creatinine , Cyclosporine , Delayed Graft Function , Graft Survival , Kidney Transplantation , Retrospective Studies , Risk Factors , Tissue Donors , TransplantsABSTRACT
BACKGROUND: Melasma is a common pigmentary disorder of facial skin. It can have significant emotional, social, and psychological effects. But little is known about the impact of melasma on the quality of life (QOL) in Korean patients. OBJECTIVE: The purpose of this study was to investigate the quality of life in patients with melasma. METHODS: A total of 100 patients with melasma were enrolled and interviewed against the Melasma Quality of Life scale (MELASQOL), which was recently developed by Balkrishnan et al. The patients were also evaluated by the investigator using the Melasma Area and Severity Index (MASI). RESULTS: The average score of MELASQOL was 41.2. A high score meant that melasma had a great effect on quality of life. It was high in patients with high MASI scores (p<0.01), young patients (p<0.01), and short duration of melasma (p<0.05). It was also high in those who had a high education level (p<0.05), or a previous treatment history (p<0.01). However, presence or absence of other skin diseases or preceding causes made no significant difference. CONCLUSION: This study shows that melasma has significant impact on the QOL of Korean melasma patients. Therefore, in addition to treating melasma, clinicians need to consider the psychosocial aspects of improving QOL in order to give patients optimal satisfaction.
Subject(s)
Humans , Education , Melanosis , Quality of Life , Research Personnel , Skin , Skin DiseasesABSTRACT
Castleman's disease, also known as angiofollicular lymphoid hyperplasia or giant lymph-node hyperplasia, is an unusual form of a lymphoproliferative disorder, and is divided clinically into a solitary and a multicentric form. The multicentric form of Castleman's disease is almost always of the plasma cell type. This can coexist with Kaposi's sarcoma in some cases. Kaposi's sarcoma is a multicentric, proliferative, vascular tumor involving cutaneous and visceral tissue. Iatrogenically-developed, immunosuppression-associated Kaposi's sarcoma is usually the result of immunosuppressive therapy. A 61-year-old man diagnosed as the plasma cell type of Castleman's disease, who had been treated with prednisolone for 2 years, was referred to the department of dermatology with numerous skin lesions consisting of confluent, violaceous-colored papules and plaques on his palm and soles. Histologic examination of the cutaneous lesions showed consistency with Kaposi's sarcoma. We report a rare case of Kaposi's sarcoma associated with multicentric Castleman's disease.
Subject(s)
Humans , Middle Aged , Dermatology , Castleman Disease , Herpesvirus 8, Human , Hyperplasia , Lymphoproliferative Disorders , Plasma Cells , Prednisolone , Sarcoma, Kaposi , SkinABSTRACT
PURPOSE: The current standard of treatment of deep vein thrombosis is anticoalgulation therapy. However, this treatment does not rapidly relieve the clot burden and clinical symptoms. In this article, we evaluate the results of thrombolysis and thrombectomy with selective endovascular stent placement for treating acute and chronic deep vein thrombosis (DVT). METHOD: During a 30 months period, 15 patients were treated with catheter-directed thrombolysis and thrombectomy with/or selective endovascular stent placement. 14 patients had symptoms for less than 14 days, 1 patient had symptoms for 28 days, 1 patient had recurrent symptoms and 10 patients had iliac vein stenosis. The primary end points of treatment was angiographic evidence of restoration of venous patency at completion of the procedure. Oral anticoagulation was continued for at least six month or longer. RESULTS: All the patients were treated with catheter directed thrombolysis and thrombectomy. In addition, endovascular stent were placed in 10 patients who had proximal venous stricture, expecially in the left common iliac vein. All patients achieved complete restoration of venous patency and there was no abnormality on blood flow. One patients was retreated with thrombolysis due to remnant thrombus, 2 patients had recurrence, and they was re-treated with conventional oral anticoagulation. CONCLUSION: Catheter-directed thrombolysis and/or thrombectomy with/or selective endovascular stent placement are effective alternatives to systemic anticoagulation for the treatment of acute and chronic DVT. More studies are needed to determine the specific indications and to validate the long-term efficacy.
Subject(s)
Humans , Catheters , Constriction, Pathologic , Iliac Vein , Lower Extremity , Recurrence , Stents , Thrombectomy , Thrombosis , Venous ThrombosisABSTRACT
PURPOSE: The current standard of treatment of deep vein thrombosis is anticoalgulation therapy. However, this treatment does not rapidly relieve the clot burden and clinical symptoms. In this article, we evaluate the results of thrombolysis and thrombectomy with selective endovascular stent placement for treating acute and chronic deep vein thrombosis (DVT). METHOD: During a 30 months period, 15 patients were treated with catheter-directed thrombolysis and thrombectomy with/or selective endovascular stent placement. 14 patients had symptoms for less than 14 days, 1 patient had symptoms for 28 days, 1 patient had recurrent symptoms and 10 patients had iliac vein stenosis. The primary end points of treatment was angiographic evidence of restoration of venous patency at completion of the procedure. Oral anticoagulation was continued for at least six month or longer. RESULTS: All the patients were treated with catheter directed thrombolysis and thrombectomy. In addition, endovascular stent were placed in 10 patients who had proximal venous stricture, expecially in the left common iliac vein. All patients achieved complete restoration of venous patency and there was no abnormality on blood flow. One patients was retreated with thrombolysis due to remnant thrombus, 2 patients had recurrence, and they was re-treated with conventional oral anticoagulation. CONCLUSION: Catheter-directed thrombolysis and/or thrombectomy with/or selective endovascular stent placement are effective alternatives to systemic anticoagulation for the treatment of acute and chronic DVT. More studies are needed to determine the specific indications and to validate the long-term efficacy.
Subject(s)
Humans , Catheters , Constriction, Pathologic , Iliac Vein , Lower Extremity , Recurrence , Stents , Thrombectomy , Thrombosis , Venous ThrombosisABSTRACT
No abstract available.
ABSTRACT
No abstract available.
Subject(s)
Animals , Mice , Coculture Techniques , Embryonic StructuresABSTRACT
No abstract available.